Literature DB >> 26914910

Chronic HIV-1 Infection Induces B-Cell Dysfunction That Is Incompletely Resolved by Long-Term Antiretroviral Therapy.

Laila N Abudulai1, Sonia Fernandez, Karli Corscadden, Michael Hunter, Lea-Ann S Kirkham, Jeffrey J Post, Martyn A French.   

Abstract

OBJECTIVES: To determine the effect of long-term antiretroviral therapy (ART) on HIV-1-induced B-cell dysfunction.
DESIGN: Comparative study of ART-naive and ART-treated HIV-infected patients with non-HIV controls.
METHODS: B-cell dysfunction was examined in patients with HIV-1 infection (n = 30) who had received ART for a median time of 9.25 years (range: 1.3-21.7) by assessing proportions of CD21 B cells (a marker of B-cell exhaustion) and proportions of tumor necrosis factor-related apoptosis-inducing ligand or B and T lymphocyte attenuator B cells, and serum levels of immunoglobulin free light chains (markers of B-cell hyperactivation). The association of these markers with serum levels of IgG1 and IgG2, and production of IgG antibodies after vaccination with pneumococcal polysaccharides were also examined. ART-naive patients with HIV (n = 20) and controls (n = 20) were also assessed for comparison.
RESULTS: ART-treated patients had increased proportions of CD21 and tumor necrosis factor-related apoptosis-inducing ligand B cells and, furthermore, although proportions of B and T lymphocyte attenuator B cells were not significantly different from controls, they correlated negatively with CD21 B cells. Proportions of CD21 B cells also correlated negatively with current CD4 T-cell counts. In ART-naive patients with HIV, free light chains correlated with CD21 B cells and IgG1, but not IgG2. Serum IgG2:IgG1 ratios were substantially lower than normal in patients with HIV and did not resolve on ART. In ART-treated patients, IgG antibody responses to pneumococcal polysaccharides after vaccination were not associated with markers of B-cell dysfunction.
CONCLUSIONS: B-cell dysfunction persists in patients with HIV receiving long-term ART. The causes and consequences of this require further investigation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26914910     DOI: 10.1097/QAI.0000000000000869

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  14 in total

Review 1.  Immunosenescence and hurdles in the clinical management of older HIV-patients.

Authors:  Marco Ripa; Stefania Chiappetta; Giuseppe Tambussi
Journal:  Virulence       Date:  2017-02-21       Impact factor: 5.882

2.  Effect of Antiretroviral Therapy on the Memory and Activation Profiles of B Cells in HIV-Infected African Women.

Authors:  Ramla F Tanko; Andreia P Soares; Tracey L Müller; Nigel J Garrett; Natasha Samsunder; Quarraisha Abdool Karim; Salim S Abdool Karim; Catherine Riou; Wendy A Burgers
Journal:  J Immunol       Date:  2016-12-30       Impact factor: 5.422

3.  Determinants of B-Cell Compartment Hyperactivation in European Adolescents Living With Perinatally Acquired HIV-1 After Over 10 Years of Suppressive Therapy.

Authors:  Alessandra Ruggiero; Giuseppe Rubens Pascucci; Nicola Cotugno; Sara Domínguez-Rodríguez; Stefano Rinaldi; Alfredo Tagarro; Pablo Rojo; Caroline Foster; Alasdair Bamford; Anita De Rossi; Eleni Nastouli; Nigel Klein; Elena Morrocchi; Benoit Fatou; Kinga K Smolen; Al Ozonoff; Michela Di Pastena; Katherine Luzuriaga; Hanno Steen; Carlo Giaquinto; Philip Goulder; Paolo Rossi; Ofer Levy; Savita Pahwa; Paolo Palma
Journal:  Front Immunol       Date:  2022-03-31       Impact factor: 7.561

Review 4.  The Significance of Type-I Interferons in the Pathogenesis and Therapy of Human Immunodeficiency Virus 1 Infection.

Authors:  Bowen Wang; Wen Kang; Jiahui Zuo; Wenzhen Kang; Yongtao Sun
Journal:  Front Immunol       Date:  2017-11-01       Impact factor: 7.561

5.  Production of IgG antibodies to pneumococcal polysaccharides is associated with expansion of ICOS+ circulating memory T follicular-helper cells which is impaired by HIV infection.

Authors:  Laila N Abudulai; Sonia Fernandez; Karli Corscadden; Sally A Burrows; Michael Hunter; M Christian Tjiam; Lea-Ann S Kirkham; Jeffrey J Post; Martyn A French
Journal:  PLoS One       Date:  2017-05-02       Impact factor: 3.240

6.  Longitudinal dynamics of the HIV-specific B cell response during intermittent treatment of primary HIV infection.

Authors:  Godelieve J de Bree; Adam K Wheatley; Rebecca M Lynch; Madhu Prabhakaran; Marlous L Grijsen; Jan M Prins; Stephen D Schmidt; Richard A Koup; John R Mascola; Adrian B McDermott
Journal:  PLoS One       Date:  2017-03-15       Impact factor: 3.240

7.  Higher Serum Immunoglobulin G3 Levels May Predict the Development of Multiple Sclerosis in Individuals With Clinically Isolated Syndrome.

Authors:  Stephanie Trend; Anderson P Jones; Lilian Cha; Scott N Byrne; Sian Geldenhuys; Marzena J Fabis-Pedrini; William M Carroll; Judith M Cole; David R Booth; Robyn M Lucas; Allan G Kermode; Martyn A French; Prue H Hart
Journal:  Front Immunol       Date:  2018-07-13       Impact factor: 7.561

8.  Relationship Between Anemia, Malaria Coinfection, and Kaposi Sarcoma-Associated Herpesvirus Seropositivity in a Population-Based Study in Rural Uganda.

Authors:  Angela Nalwoga; Stephen Cose; Stephen Nash; Wendell Miley; Gershim Asiki; Sylvia Kusemererwa; Robert Yarchoan; Nazzarena Labo; Denise Whitby; Robert Newton
Journal:  J Infect Dis       Date:  2018-08-24       Impact factor: 5.226

9.  HIV-1 Transactivator of Transcription (Tat) Co-operates With AP-1 Factors to Enhance c-MYC Transcription.

Authors:  Leonardo Alves de Souza Rios; Lungile Mapekula; Nontlantla Mdletshe; Dharshnee Chetty; Shaheen Mowla
Journal:  Front Cell Dev Biol       Date:  2021-06-30

Review 10.  Antiviral Functions of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific IgG Antibodies: Effects of Antiretroviral Therapy and Implications for Therapeutic HIV-1 Vaccine Design.

Authors:  Martyn A French; M Christian Tjiam; Laila N Abudulai; Sonia Fernandez
Journal:  Front Immunol       Date:  2017-07-04       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.